

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K/A

Current report filing [amend]

Filing Date: **2013-01-11** | Period of Report: **2012-08-13**  
SEC Accession No. [0001193125-13-010893](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**PATHEON INC**

CIK: [1400431](#) | IRS No.: **000000000** | Fiscal Year End: **1031**  
Type: **8-K/A** | Act: **34** | File No.: [000-54283](#) | Film No.: **13526109**  
SIC: **2834** Pharmaceutical preparations

Mailing Address  
7070 MISSISSAUGA ROAD,  
SUITE 350  
MISSISSAUGA ON A6  
L5N7J8

Business Address  
C/O PATHEON  
PHARMACEUTICALS  
SERVICES INC  
4721 EMPEROR  
BOULEVARD, SUITE 200  
DURHAM NC 27703  
905-821-4001

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K/A  
(Amendment No. 1)**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 13, 2012**

---

**PATHEON INC.**

**(Exact name of registrant as specified in its charter)**

---

**Canada**  
(State or other jurisdiction  
of incorporation)

**000-54283**  
(Commission  
File Number)

**Not Applicable**  
(IRS Employer  
Identification No.)

**c/o Patheon Pharmaceuticals Services Inc.**

**4721 Emperor Boulevard, Suite 200**

**Durham, NC**

(Address of principal executive offices)

**27703**

(Zip Code)

**Registrant's telephone number, including area code: (919) 226-3200**

**Not Applicable**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

## EXPLANATORY NOTE

This Amendment No. 1 on Form 8-K/A (the “Amended Form 8-K”) for Patheon Inc. (the “Company”) amends the Current Report on Form 8-K originally filed with the Securities and Exchange Commission on August 13, 2012 disclosing the separation from the Company of Mark J. Kontny, Ph.D. (the “Original Form 8-K”). This Amended Form 8-K is being filed to disclose the entry by Dr. Kontny and the Company into the Agreement (as defined below). Except for the disclosures related to the Agreement, the disclosures made in this Amended Form 8-K are as of August 13, 2012, the date of the Original Form 8-K, and have not been amended, updated or otherwise modified.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 13, 2012, Patheon Inc. (the “Company”) announced that Mark J. Kontny, Ph.D., President, Global Pharmaceutical Development Services and Chief Scientific Officer, is no longer employed by the Company, effective as of this date.

A copy of the press release announcing Dr. Kontny’s separation is attached hereto as Exhibit 99.1.

On January 8, 2013, Patheon Pharmaceuticals Services Inc., an indirect wholly owned subsidiary of the Company, and Dr. Kontny entered into a Severance and Release of Claims Agreement (the “Agreement”). Pursuant to the Agreement, Dr. Kontny will receive a total of \$520,000, payable in 12 equal monthly installments, in exchange for providing the Company and its affiliates a customary release of claims and agreeing to abide by customary confidentiality, nondisparagement and cooperation provisions.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 11, 2013

**PATHEON INC.**

By: /s/ Stuart Grant

Stuart Grant

Executive Vice President, Chief Financial Officer